Clinical trial · Interventional
Combination of Proton Therapy With Immunotherapy in Multiple Metastases Cancer
A Phase I/II Study of Combination of Proton Therapy With Immunotherapy in Multiple Metastases Cancer
NCT03765190CI-TRIAL-00036012PI-MMCunknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using proton radiation therapy in combination with immunotherapy(ie. Programmed cell death protein 1, also known as PD-1 antibody) in multiple metastases.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Immunotherapy | — | UNRESOLVED | — |
| Neoplasm Metastasis | — | UNRESOLVED | — |
| Proton Therapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiation: Proton Therapy+PD-1 Ab | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Radiation: Proton Therapy+PD-1 Ab
- description
- proton radiotherapy concurrent with immunotherapy(ie. PD-1 Ab for 1 year)
- interventionNames
- Combination Product: Radiation: Proton Therapy+PD-1 Ab
Primary outcomes (1)
- measure
- Adverse events
- timeFrame
- Through 1 years after completion of treatment
- description
- Assess adverse events according to CTCAE4.0
Secondary outcomes (2)
- measure
- Progression-free survival (PFS)
- timeFrame
- Through 2 years after completion of treatment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed Unspecified Adult Solid Tumor * Multiple metastatic tumors * Intending to be treated with proton beam and immunotherapy * Age ≥ 18 years old * KPS≥70 * Signed written informed consent. Exclusion Criteria: * Pregnant or breastfeeding woman * Patient under guardianship or tutorship * Patients or legal guardians who are unable to understand informed consent document
References
Publications (0)
Data not yet available
No reference posted for this study.